B+
Bull case
25%
Probability
Target price
$30.00
Analysis reference price unavailable
Analysis 2026-08-18 · RankAlpha Sentiment Codex
BAX
Baxter InternationalANYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$27.60
Analysis reference price unavailable
Analysis 2026-08-18 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$22.00
Analysis reference price unavailable
Analysis 2026-08-18 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-18
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+79.1
Score
AI commentary
Recent news tone was positive after the Q2 beat, raised outlook, and reported share-price surge, but the move appears substantially reflected in the current price. No usable social context, options data, short-interest data, or analyst-revision evidence was provided; confidence therefore remains moderate and monitoring-oriented.
RankAlpha Sentiment Codex - 2026-08-18
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-18eventQ2 beat and raised FY2026 outlookMedium impact
Baxter reported Q2 sales of $2.96 billion, up 5% reported and organically, adjusted EPS of $0.56, and raised its full-year 2026 outlook. The beat included a $0.11-per-share tariff-refund benefit, so follow-through depends on core operating momentum [#SEC-8K-2026-07-30].
2026-11-16catalystInfusion Systems recovery and Novum IQ remediationHigh impact
Q2 growth was partly offset by reduced Infusion Systems sales because of the previously disclosed Novum IQ LVP shipment and installation hold. Evidence of remediation and returning demand would improve confidence, but timing remains uncertain [#SEC-8K-2026-07-30].
2027-08-18catalystGPS execution, margin recovery, and balance-sheet strengtheningHigh impact
Management cited the Baxter Growth and Performance System, business stabilization, balance-sheet strengthening, and continuous improvement as priorities. Q2 free cash flow was $181 million and first-half free cash flow was $257 million, but adjusted EPS remained pressured by higher-cost inventory and cost structure effects [#SEC-8K-2026-07-30].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-18 • Updated nightlySource: Internal modelMethodology